A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects

Phase 1 Completed 36 enrolled Abbott

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of three different strengths of an investigational product dosed twice a day over 7 days in healthy subjects.

Timeline

Start: 2009-03
Primary completion: 2009-06
Completion: —

Publications

Rowbotham MC, Nothaft W, Duan RW, Wang Y, Faltynek C, McGaraughty S, Chu KL, Svensson P. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain. 2011 May;152(5):1192-1200. doi: 10.1016/j.pain.2011.01.051. Epub 2011 Mar 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	ABT-102	Small molecule	1 mg	—
Comparator	ABT-102	Small molecule	2 mg	—
Comparator	ABT-102	Small molecule	4 mg	—

Indications

No indication recorded.